Search Results
May 01, 2026, 04:05 ET ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
Company.About ADC TherapeuticsADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA® (loncastuximab tesirine-lpyl).ADC Therapeutics'
More news about: ADC Therapeutics SA
May 01, 2026, 00:35 ET Piramal Pharma Limited annuncia i risultati del quarto trimestre e dell'intero esercizio 2026
registrano un aumento della domanda dovuto al cambiamento delle preferenze geografiche dei clienti e alla forte crescita in settori di nicchia quali ADC, HPAPI, prodotti iniettabili on-shore e capacità di produzione di prodotti farmaceutici.Investimenti in conto capitale (Capex) pari a 90
More news about: Piramal Pharma Limited
Apr 30, 2026, 16:19 ET Piramal Pharma Limited、FY26第4四半期および通期決算を発表
米国のバイオファーマ資金調達の拡大（FY26下半期に前年同期比75%増、FY26通期で30%増）とM&A活動に牽引され、FY26下半期のRFPと受注流入は堅調に推移しました。（業界出典）顧客の地域選好の変化や、 ADC、HP API、オンショア注射剤、製剤能力といった差別化分野での力強い成長により、海外拠点では、需要が増加しています。9,000万米ドルの 設備投資は順調で、レキシントンおよびリバービューの拠点で無菌注射剤とペイロードリンカーの生産能力を拡大する計画に
More news about: Piramal Pharma Limited
Apr 30, 2026, 16:10 ET Piramal Pharma Limited annonce ses résultats pour le quatrième trimestre et l'exercice 2026
de la demande grâce à l'évolution des préférences géographiques des clients et à une forte croissance dans des domaines différenciés, comme les ADC, les HP API, capacités nationales de produits injectables et de produits pharmaceutiques.Dépenses d'investissement de
More news about: Piramal Pharma Limited
Apr 30, 2026, 09:22 ET /C O R R E C T I O N -- American-Arab Anti-Discrimination Committee/
nationwide. ADC is committed to ensuring that does not happen," said ADC staff attorney Malak Afaneh. "ADC calls on the City of Medford to mount a full and vigorous defense of the ordinance and urges the court to grant the Motion to Intervene without delay."ABOUT THE ADCThe
More news about: American-Arab Anti-Discrimination Committee
Apr 30, 2026, 00:26 ET 2026 ESMO GC | Mabwell to Present Latest Clinical Data on 9MW2821 for Cervical Cancer in Oral and Poster Presentations
biopharmaceutical company with a fully integrated industry chain, today announced that two latest clinical study results of its novel Nectin‑4 targeting ADC (R&D code: 9MW2821) in cervical cancer will be presented respectively as an oral presentation and a poster presentation, at the 2026 European Society
More news about: Mabwell
Apr 29, 2026, 19:00 ET Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca
extracellular proteins, offering a differentiated mechanism of action and durable therapeutic benefit. Pinetree is also advancing trispecific degraders and ADC-integrated platforms.For more information, visit
More news about: PineTree Therapeutics
Apr 29, 2026, 14:27 ET Piramal Pharma Limited anuncia los resultados del cuarto trimestre y del ejercicio fiscal 2026
experimentando una creciente demanda debido a los cambios en las preferencias geográficas de los clientes y un fuerte crecimiento en áreas diferenciadas como ADC, HP API, inyectables de producción nacional y capacidades de producción de medicamentos.Se prevé una inversión de capital de 90 millones
More news about: Piramal Pharma Limited
Apr 29, 2026, 10:00 ET European Commission (EC) Approves Henlius and Organon's POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe
more than 40 markets worldwide with an accelerated globalisation process. In parallel, multiple high-potential innovative assets—including the PD-L1 ADC HLX43 and the novel epitope anti-HER2 mAb HLX22—are advancing through global pivotal clinical development. Supported by a biologics manufacturing network
More news about: Henlius
Apr 29, 2026, 06:09 ET 復宏漢霖與Organon共同宣佈歐洲首個帕妥珠單抗生物類似藥POHERDY®獲歐盟委員會批准
）潛力，並在全球同步推進30餘項臨床研究。核心產品H藥 漢斯狀®（斯魯利單抗，歐洲商品名：Hetronifly®）作為全球首個獲批一線治療小細胞肺癌的抗PD-1單抗，正加速全球佈局，已在全球40餘個市場獲批上市；同時，多款潛力創新資產，包括PD-L1 ADC HLX43及新表位HER2單抗HLX22正全面推進全球關鍵性臨床研究。依托通過中、歐、美三地GMP認證的生產體系，復宏漢霖已建成總產能達84,000升的生物藥生產平台，形成覆蓋全球六大洲的穩定供應網絡。未來，復宏漢霖將始終堅持以患者為中心，聚焦未滿足的臨床需求，持續推動創新成果向臨床價值與患者可
More news about: 復宏漢霖
Apr 28, 2026, 15:51 ET Piramal Pharma Limited Announces Results for Q4 and Full-year FY26
Source)Overseas sites seeing rising demand from shifting customer geographical preferences and strong growth in differentiated areas such as ADC, HP API, on‑shore injectables and drug product capabilities.US$90Mn Capex on track to scale sterile injectable and payload-linker capacities
More news about: Piramal Pharma Limited
Apr 28, 2026, 15:40 ET Piramal Pharma Limited Announces Results for Q4 and Full-year FY26
Source)Overseas sites seeing rising demand from shifting customer geographical preferences and strong growth in differentiated areas such as ADC, HP API, on‑shore injectables and drug product capabilities.US$90Mn Capex on track to scale sterile injectable and payload-linker capacities
More news about: Piramal Pharma Limited
Apr 28, 2026, 10:54 ET Fosun Pharma Announces Q1 2026 Results: Net Profit Attributable to Shareholders After Deducting Non-Recurring Gains and Losses Increased by 21.96% YoY, With Strong Pipeline Execution
also focused on strengthening core technology platforms such as antibodies/ADC, small molecules, and cell therapy, continuously consolidating its innovation moat in core therapeutic areas including oncology.In the field of antibody/ADC technology platform, Shanghai Henlius, a subsidiary of Fosun
More news about: Fosun Pharma
Apr 28, 2026, 10:38 ET 復星國際：創造可持續影響 發佈2025年ESG報告及氣候信息披露報告
中外文化交流的重要載體，持續向世界講述「中國故事」，傳遞可持續生活的美好願景。創新驅動，為患者帶來治癒希望復星堅持創新驅動，秉持為更多患者帶來治癒希望的初心。旗下健康產業圍繞未被滿足的臨床需求，深度佈局腫瘤、免疫炎症、神經退行性疾病等核心治療領域，積極拓展慢病及罕見病等領域，打造具有長期競爭力的產品管線與綜合解決方案。同時，持續夯實抗體、ADC、小分子、細胞治療等核心技術平台，並拓展核藥、小核酸等前沿技術。其中，漢斯狀、HLX43、HLX22等上市及在研創新藥實現多項「全球首個」突破。漢斯狀®成為全球首個一線治療廣泛期小細胞肺癌的PD-1
More news about: 復星
Apr 28, 2026, 07:37 ET Arcera Life Sciences and Fosun Pharma launch long-term collaboration framework
solutions. Meanwhile, Fosun Pharma has consolidated its core technical platforms including but not limited to antibodies and antibody-drug conjugates (ADC), small molecules and cell therapy. Additionally, we also actively advance cutting-edge therapeutic modalities such as radiopharmaceuticals and small
More news about: Fosun Pharma
Apr 28, 2026, 04:07 ET Ivonescimab Receives Major Recommendations Across Multiple Therapies in the 2026 CSCO NSCLC Guideline
established a robust R&D innovation ecosystem centered on its Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.
More news about: Akeso, Inc.
Apr 27, 2026, 07:30 ET ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026
call.About ADC TherapeuticsADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA® (loncastuximab tesirine-lpyl).ADC Therapeutics'
More news about: ADC Therapeutics SA
Apr 24, 2026, 15:33 ET AMERICAN-ARAB ANTI-DISCRIMINATION COMMITTEE (ADC) APPOINTS JENIN YOUNES INTERIM PRESIDENT
period, based upon her qualifications and the Board's confidence in her ability to lead ADC forward with authority and focus. ABOUT THE ADC The American-Arab Anti-Discrimination Committee (ADC) is the largest Arab American grassroots organization in the United States, founded in 1980
More news about: American-Arab Anti-Discrimination Committee
Apr 23, 2026, 09:30 ET Servier finalise l'acquisition de Day One Biopharmaceuticals
tovorafenib, qui fait l'objet d'études dans d'autres indications, le pipeline de Day One comprend Emi-Le (emiltatug ledadotin), un nouvel anticorps-conjugué (ADC) et DAY301, une thérapie ciblée dans les cancers rares.« Accueillir Day One au sein de Servier ouvre un nouveau chapitre de notre expansion
More news about: Servier
Apr 23, 2026, 08:30 ET Servier completes the acquisition of Day One Biopharmaceuticals
tovorafenib, which is being investigated in additional indications, Day One's pipeline includes Emi-Le (emiltatug ledadotin), a novel antibody drug conjugate (ADC) and DAY301, a targeted therapy in rare cancers. "Welcoming Day One to Servier marks an important next chapter in how we are expanding our presence
More news about: Servier
Apr 23, 2026, 08:30 ET Servier completes the acquisition of Day One Biopharmaceuticals
tovorafenib, which is being investigated in additional indications, Day One's pipeline includes Emi-Le (emiltatug ledadotin), a novel antibody drug conjugate (ADC) and DAY301, a targeted therapy in rare cancers. "Welcoming Day One to Servier marks an important next chapter in how we are expanding our presence
More news about: Servier
Apr 23, 2026, 04:14 ET Mabwell Initiates Phase III Clinical Study of its Nectin-4-Targeting ADC 9MW2821 for the Treatment of Triple-Negative Breast Cancer
announces the initiation of a Phase III clinical study of its proprietary Nectin-4-targeting ADC (R&D code: 9MW2821) for the treatment of triple-negative breast cancer (TNBC). 9MW2821 is the world's first Nectin-4 ADC to enter Phase III clinical study for TNBC. This marks the fourth pivotal trial initiated
More news about: Mabwell
Apr 23, 2026, 03:38 ET 邁威生物靶向Nectin-4 ADC創新藥 9MW2821 啟動治療三陰性乳腺癌的III期臨床研究
TOPi-ADC 已成為 TNBC 標准療法之後的主要治療手段。既往 TOPi-ADC 治療失敗的 TNBC 患者治療仍以化療為主，有較大未被滿足的臨床需求。9MW2821 是全球首個披露 TNBC 有效性數據的靶向 Nectin-4 ADC，曾獲 FDA 授予「快速通道認定」（FTD）用於治療局部晚期或轉移性 Nectin-4 陽性 TNBC。TNBC 是其繼尿路上皮癌（UC）、宮頸癌（CC）後，第 3 個進入 III 期臨床研究階段的腫瘤類型。目前，9MW2821 也已在美國針對 ADC 經治 TNBC
More news about: 邁威生物
Apr 23, 2026, 02:47 ET 2026 ASCO | Mabwell to Present Latest Clinical Data on 9MW2821 Combined with Toripalimab for Urothelial Carcinoma in Oral and Poster Presentations
innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that two latest clinical study results of its Nectin-4-targeting ADC 9MW2821 in combination with toripalimab for urothelial carcinoma will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
More news about: Mabwell
Apr 23, 2026, 02:05 ET 2026 ASCO | 邁威生物將以口頭報告和壁報形式公布 9MW2821 聯合特瑞普利單抗用於尿路上皮癌的最新臨床數據
2026年4月23日 /美通社/ -- 邁威生物（688062.SH），一家全產業鏈布局的創新型生物製藥公司，宣布將於當地時間 2026 年 5 月 29 日 - 6 月 2 日在美國芝加哥舉行的 2026 美國臨床腫瘤學會（ASCO）年會分別以口頭報告和壁報形式公布靶向 Nectin-4 ADC 創新藥 9MW2821 聯合特瑞普利單抗用於尿路上皮癌的兩項最新臨床研究結果。 口頭報告摘要標題： Bulumtatug fuvedotin (BFv; 9MW2821) plus toripalimab in patients with
More news about: 邁威生物